PARTICIPATION OF BIOMARKERS FABP4, ENDOCAN, PAI-1 TO THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN PREDIABETES CONDITION: УЧАСТИЕ БИОМАРКЕРОВ FABP4, ENDOCAN, PAI-1 В РАЗВИТИИ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В УСЛОВИЯХ ПРЕДИАБЕТА

Συγγραφείς: Parakhina, V.F., Laryushina, Ye.M., Ponomareva, O.A.

Πηγή: Наука и здравоохранение. :181-190

Θεματικοί όροι: cardiovascular events, жүрек-тамыр жағдайлары, биомаркерлер, biomarkers, сердечно-сосудистые события, биомаркеры, prediabetes, эндотелиальная дисфункция, эндотелиалды дисфункция, 16. Peace & justice, преддиабет, endothelial dysfunction, 3. Good health

Remote cardiovascular events in patients with psoriasis, coronary heart disease and their combination ; Отдаленные сердечно-сосудистые события у пациентов с псориазом, ишемической болезнью сердца и их сочетанием

Συγγραφείς: A. M. Amineva, I. A. Lakman, E. A. Badykova, M. N. Shamuratov, R. F. Rakhimova, Z. R. Khismatullina, A. I. Mezenceva, N. Sh. Zagidullin, А. М. Аминева, И. А. Лакман, Е. А. Бадыкова, М. Н. Шамуратов, Р. Ф. Рахимова, З. Р. Хисматуллина, А. И. Мезенцева, Н. Ш. Загидуллин

Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 40, № 1 (2025); 110-119 ; Сибирский журнал клинической и экспериментальной медицины; Том 40, № 1 (2025); 110-119 ; 2713-265X ; 2713-2927

Θεματικοί όροι: госпитализация, coronary heart disease, unfavorable cardiovascular endpoints, mortality, hospitalizations, ишемическая болезнь сердца, неблагоприятные сердечно-сосудистые события, смертность

Περιγραφή αρχείου: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/2639/1054; Хисматуллина З.Р., Аминева А.М., Курочкин Д.П., Гареева Д.Ф., Загидуллин Н.Ш. и др. Псориаз, псориатический артрит, метаболические нарушения и сердечно-сосудистые заболевания. Что общего? Клиническая дерматология и венерология. 2020;(6):137–145. DOI:10.17116/klinderma202019021139.; Koch M., Baurecht H., Ried J.S., Rodriguez E., Schlesinger S., Volks N. et al. Psoriasis and cardiometabolic traits: Modest association but distinct genetic architectures. J. Investig. Dermatol. 2015;135(5):1283– 1293. DOI:10.1038/jid.2015.8.; Shiba M., Kato T., Funasako M., Nakane E., Miyamoto S., Izumi T. et al. Association between psoriasis vulgaris and coronary heart disease in a hospital-based population in Japan. PLoS One. 2016;11(2):e0149316. DOI:10.1371/journal.pone.0149316.; Dowlatshahi E.A., Kavousi M., Nijsten T., Ikram M.A., Hofman A., Franco O.H. et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study. J. Invest. Dermatol. 2013;133(10):2347–2354. DOI:10.1038/jid.2013.131.; Hadi Y., Or T., Moady G., Atar S. Psoriasis and coronary heart disease – not as severe as predicted. QJM. 2022;115(6):388–392. DOI:10.1093/qjmed/hcab173.; Yeung H., Takeshita J., Mehta N.N., Kimmel S.E., Ogdie A., Margolis D.J. et al. Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol. 2013;149(10):1173–1179. DOI:10.1001/jamadermatol.2013.5015.; Takeshita J., Grewal S., Langan S.M., Mehta N.N., Ogdie A., Van Voorhees A.S. et al. Psoriasis and comorbid diseases: Implications for management. J. Am. Acad. Dermatol. 2017;76(3):393–403. DOI:10.1016/j.jaad.2016.07.065.; Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. DOI:10.1001/jama.296.14.1735.; Wakkee M., Herings R.M., Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J. Invest. Dermatol. 2010;130(4):962–967. DOI:10.1038/jid.2009.321.; Реброва Н.В., Саркисова О.Л., Рипп Т.М., Карпов Р.С., Мордовин В.Ф. Цереброваскулярная реактивность у пациентов с сочетанием ревматоидного артрита и артериальной гипертензии. Научно-практическая ревматология. 2022;60(3):369–373. DOI:10.47360/1995-4484-2022-369-373.; Аминева А.М., Лакман И.А., Бадыкова Е.А., Рахимова Р.Ф., Дождев С.С. Попов Д.В. и др. Сывороточные биомаркеры у пациентов с псориазом и ишемической болезнью сердца и их влияние на госпитализацию в проспективном 4-летнем одноцентровом неконтролируемом исследовании. Росскийский кардиологический журнал. 2024; 29 (1): 24–30. DOI:10.15829/1560-4071-2024-5766.; Liu L ., Cui S., Liu M., Huo X., Zhang G. , Wang N. Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Front. Cardiovasc. Med. 2022;25(9):829709. DOI:10.3389/fcvm.2022.829709.; https://www.sibjcem.ru/jour/article/view/2639

Διαθεσιμότητα: https://www.sibjcem.ru/jour/article/view/2639
https://doi.org/10.29001/2073-8552-2025-40-1-110-119

PARTICULARITĂȚILE CLINICO-HEMODINAMICE ALE PACIENȚILOR CU INFARCT MIOCARDIC ACUT CU ELEVAREA SEGMENTULUI ST SUPUȘI TRATAMENTULUI INTERVENȚIONAL TARDIV

Συγγραφείς: Abraş, M.D., Surev, A.I., Esanu, A., Grib, A.L., Vreme, C.

Πηγή: Buletinul Academiei de Ştiinţe a Moldovei: Ştiinţe Medicale, Vol 75, Iss 1, Pp 27-32 (2023)
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 75 (1) 27-32

Θεματικοί όροι: Medicine (General), evenimente cardiovasculare majore, infarct miocardic acut cu supradenivelarea segmentului ST, major cardiovascular events, infarct miocardic acut cu supradenivelarea segmentului st, большие сердечно-сосудистые события, RC31-1245, ST-segment elevation myocardial infarction, ранняя и поздняя интервенционная реперфузия миокарда, Other systems of medicine, R5-920, инфаркт миокарда с подъемом сегмента ST, revascularizare miocardică intervențională precoce și tardivă, Public aspects of medicine, RA1-1270, Internal medicine, early and late myocardial intervențional reperfusion, RZ201-999

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://doaj.org/article/e1de487c40b84891982dcdf4e2b06da5
https://ibn.idsi.md/vizualizare_articol/182159

Cardiovascular Events in Patients with Community-Acquired Pneumonia

Πηγή: Кардиология в Беларуси. :578-591

Θεματικοί όροι: 03 medical and health sciences, cardiovascular events, comorbidity, 0302 clinical medicine, community-acquired pneumonia, коморбидность, внебольничная пневмония, сердечно-сосудистые события, risk stratification, стратификация риска, 3. Good health

Echogenicity of carotid atherosclerotic plaques as a predictor of adverse cardiovascular events in patients aged 40–64: prospective study ; Эхогенность каротидных атеросклеротических бляшек как предиктор неблагоприятных сердечно-сосудистых событий у пациентов 40–64 лет: проспективное исследование

Συγγραφείς: V. V. Genkel, A. S. Kuznetcova, E. V. Lebedev, A. O. Salashenko, A. Yu. Savochkina, V. A. Sumerkina, K. V. Nikushkina, L. R. Pykhova, I. I. Shaposhnik, В. В. Генкель, А. С. Кузнецова, Е. В. Лебедев, А. О. Салашенко, А. Ю. Савочкина, В. А. Сумеркина, К. В. Никушкина, Л. Р. Пыхова, И. И. Шапошник

Πηγή: Diagnostic radiology and radiotherapy; Том 14, № 3 (2023); 39-45 ; Лучевая диагностика и терапия; Том 14, № 3 (2023); 39-45 ; 2079-5343

Θεματικοί όροι: каротидный атеросклероз, GSM analysis, cardiovascular events, carotid atherosclerosis, GSM-анализ, сердечно-сосудистые события

Περιγραφή αρχείου: application/pdf

Relation: https://radiag.bmoc-spb.ru/jour/article/view/902/607; Johri A.M., Nambi V., Naqvi T.Z., Feinstein S.B., Kim E.S.H., Park M.M., Becher H., Sillesen H. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography // J. Am. Soc. Echocardiogr. 2020. Vol. 33, No. 8. Р. 917–933. doi:10.1016/j.echo.2020.04.021.; Saba L., Brinjikji W., Spence J.D., Wintermark M., Castillo M., de Borst G.J., Yang Q., Yuan C., Buckler A., Edjlali M., Saam T., Saloner D., Lal B.K., Capodanno D., Sun J., Balu N., Naylor R., Lugt A.V.D., Wasserman B.A., Kooi M.E., Wardlaw J., Gillard J., Lanzino G., Hedin U., Mikulis D., Gupta A., DeMarco J.K., Hess C., Goethem J.V., Hatsukami T., Rothwell P., Brown M.M., Moody A.R. Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement // AJNR Am. J. Neuroradiol. 2021. Vol. 42, No. 9. Р. 1566–1575. doi:10.3174/ajnr.A7223.; Mitchell C.C., Stein J.H., Cook TD., Salamat S., Wang X., Varghese T., Jackson D.C., Sandoval Garcia C., Wilbrand SM., Dempsey RJ. Histopathologic Validation of Grayscale Carotid Plaque Characteristics Related to Plaque Vulnerability // Ultrasound Med. Biol. 2017. Vol. 43, No. 1. Р. 129–137. doi:10.1016/j.ultrasmedbio.2016.08.011.; Mitchell C. Grayscale Analysis of Carotid Plaque: An Overview // J. Am. Soc. Echocardiogr. 2019. Vol. 2, No. 8, pp. A21-A22. doi:10.1016/j.echo.2019.06.007.; Goudot G., Khider L., Pedreira O., Poree J., Julia P., Alsac J.M., Amemiya K., Bruneval P., Messas E., Pernot M., Mirault T. Innovative Multiparametric Characterization of Carotid Plaque Vulnerability by Ultrasound // Front Physiol. 2020. Vol. 11, pp. 157. doi:10.3389/fphys.2020.00157.; Ariyoshi K., Okuya S., Kunitsugu I., Matsunaga K., Nagao Y., Nomiyama R., Takeda K., Tanizawa Y. Ultrasound analysis of gray-scale median value of carotid plaques is a useful reference index for cerebro-cardiovascular events in patients with type 2 diabetes // J. Diabetes Investig. 2015. Vol. 6, No. 1. Р. 91–97. doi:10.1111/jdi.12242.; Li Q., Liu B., Zhao Y., Liu Y., Gao M., Jia L., Jiao L., Hua Y. Echolucent carotid plaque is associated with restenosis after carotid endarterectomy // J. Neurosurg. 2020. Vol. 134, No. 3, pp. 1203–1209. doi:10.3171/2020.2.JNS193397.; Biasi G.M, Froio A., Diethrich E.B., Deleo G., Galimberti S., Mingazzini P., Nicolaides A.N., Griffin M., Raithel D., Reid D.B., Valsecchi M.G. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study // Circulation. 2004. Vol. 110, No. 6. Р. 756–762. doi:10.1161/01.CIR.0000138103.91187.E3.; Генкель В.В., Кузнецова А.С., Лебедев Е.В., Шапошник И.И. Факторы, связанные с эхогенностью атеросклеротических бляшек, у пациентов в возрасте 40– 64 лет с каротидным атеросклерозом // Кардиология. 2021; Т. 61, № 6, С. 35–40.; Стахнёва Е.М., Каштанова Е.В., Полонская Я.В., Стрюкова Е.В., Шрамко В.С., Садовский Е.В., Кургузов А.В., Мурашов И.С., Чернявский А.М., Рагино Ю.И. Изучение ассоциаций белков в крови с наличием нестабильных атеросклеротических бляшек в коронарных артериях методом количественной протеомики // Бюллетень сибирской медицины. 2022. Т. 21, № 4. С. 121–129.; Hafiane A. Vulnerable Plaque, Characteristics, Detection, and Potential Therapies // J. Cardiovasc. Dev. Dis. 2019. Vol. 6, No. 3. Р. 26. doi:10.3390/jcdd6030026.; Zhu G., Hom J., Li Y., Jiang B., Rodriguez F., Fleischmann D., Saloner D., Porcu M., Zhang Y., Saba L., Wintermark M. Carotid plaque imaging and the risk of atherosclerotic cardiovascular disease // Cardiovasc. Diagn. Ther. 2020. Vol. 10, No. 4. Р. 1048–1067. doi:10.21037/cdt.2020.03.10.; Гучаева Д.А., Трипотень М.И., Погорелова О.А., Хеймец Г.И., Шахнович Р.М., Балахонова Т.В. Эхогенность атеросклеротических бляшек в сонных артериях у больных с острым коронарным синдромом и ее влияние на прогноз сердечно-сосудистых событий // Российский кардиологический журнал. 2019, Т. 24, № 5. С. 30–36.; Khan F., Gonçalves I., Shore A.C., Natali A., Palombo C., Colhoun H.M., Östling G., Casanova F., Kennbäck C., Aizawa K., Persson M., Gooding K.M., Strain D., Looker H., Dove F., Belch J., Pinnola S., Venturi E., Kozakova M., Nilsson J. Plaque characteristics and biomarkers predicting regression and progression of carotid atherosclerosis // Cell Rep. Med. 2022. Vol. 19, No. 3. Р. 100676. doi:10.1016/j.xcrm.2022.100676.; Martínez-Sánchez P., Fernández-Domínguez J., Ruiz-Ares G., Fuentes B., Alexandrov A.V., Díez-Tejedor E. Changes in carotid plaque echogenicity with time since the stroke onset: an early marker of plaque remodeling? // Ultrasound Med. Biol. 2012. Vol. 38, No. 2, pp. 231–237. doi:10.1016/j.ultrasmedbio.2011.10.025.; Della-Morte D., Dong C., Crisby M., Gardener H., Cabral D., Elkind MSV., Gutierrez J., Sacco RL., Rundek T. Association of Carotid Plaque Morphology and Glycemic and Lipid Parameters in the Northern Manhattan Study // Front Cardiovasc. Med. 2022. Vol. 9. Р. 793755. doi:10.3389/fcvm.2022.793755.; Brunner G., Virani S.S., Sun W., Liu L., Dodge R.C., Nambi V., Coresh J., Mosley T.H., Sharrett A.R., Boerwinkle E., Ballantyne C.M., Wasserman B.A. Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events: The ARIC Carotid Magnetic Resonance Imaging Study // JAMA Cardiol. 2021. Vol. 6, No. 1. Р. 79–86. doi:10.1001/jamacardio.2020.5573.

Διαθεσιμότητα: https://radiag.bmoc-spb.ru/jour/article/view/902
https://doi.org/10.22328/2079-5343-2023-14-3-39-45

CURRENT VIEWS ON THE ROLE OF GROWTH DIFFERENTIATION FACTOR 15 IN THE GENESIS, COURSE AND OUTCOME OF CARDIOVASCULAR PATHOLOGY ; СОВРЕМЕННЫЙ ВЗГЛЯД НА РОЛЬ ФАКТОРА РОСТА И ДИФФЕРЕНЦИРОВКИ 15 В ГЕНЕЗЕ, ТЕЧЕНИИ И ИСХОДАХ ПАТОЛОГИИ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ

Συγγραφείς: Regina E. Ibragimova, Elena A. Zakharyan, Регина Энверовна Ибрагимова, Елена Аркадьевна Захарьян

Συνεισφορές: Исследование выполнено при поддержке гранта Российского научного фонда № 22-25-20053, https://rscf.ru/project/22-25-20053/

Πηγή: Complex Issues of Cardiovascular Diseases; Том 12, № 3 (2023); 211-219 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 12, № 3 (2023); 211-219 ; 2587-9537 ; 2306-1278

Θεματικοί όροι: Сердечно-сосудистые события, Endothelial dysfunction, Cardiovascular events, Эндотелиальная дисфункция

Περιγραφή αρχείου: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/1295/824; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1295/1292; Tsai V.W.W., Husaini Y., Sainsbury A., Brown D.A., Breit S.N. The MIC-1/GDF15- GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metabolism. 2018;28(3):353–368. doi:10.1016/j.cmet.2018.07.018.; Wollert K.C., Kempf T., Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clinical Chemistry. 2017;63(1):140–151. doi:10.1373/clinchem.2016.255174.; Lawton L.N., Bonaldo M.F., Jelenc P.C., Qiu L., Baumes S.A., Marcelino R.A., de Jesus G.M., Wellington S., Knowles J.A., Warburton D., Brown S., Soares M.B. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997;203 (1):17–26. doi:10.1016/s0378-1119(97)00485-x.; Fairlie W.D., Moore A.G., Bauskin A.R., Russell P.K., Zhang H.P., Breit S.N. MIC-1 is a novel TGF-β superfamily cytokine associated with macrophage activation. Journal of Leukocyte Biology.1999;65(1):2–5. doi:10.1002/jlb.65.1.2.; Coll A.P., Chen M., Taskar P., Rimmington D., Patel S., Tadross J.A., Cimino I., Yang M., Welsh P., Virtue S., et al. GDF15 Mediates the Effects of Metformin on Body Weight and Energy Balance. Nature. 2020;578(7795):444–8. doi:10.1038/s41586-019-1911-y; Du W., Piek A., Schouten E.M., van de Kolk C.W.A., Mueller C., Mebazaa A., Voors A.A., de Boer R.A., Silljé H.H.W. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics. 2018;8(15):4155–4169. doi:10.7150/thno.26055.; Wang J., Tan G.J., Han L.N., Bai Y.Y., He M., Liu H.B. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14 (2):135–150. doi:10.11909/j.issn.1671-5411.2017.02.008.; Tuegel C., Katz R., Alam M., Bhat Z., Bellovich K., de Boer I., Brosius F., Gadegbeku C., Gipson D., Hawkins J., Himmelfarb J., Ju W., Kestenbaum B., Kretzler M., Robinson-Cohen C., Steigerwalt S., Bansal N. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. Am J Kidney Dis.2018;72(4):519–528. doi:10.1053/j.ajkd.2018.03.025.; Adela R., Banerjee S.K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res. 2015;2015:490842. doi:10.1155/2015/490842.; Wallentin L., Hijazi Z., Andersson U., Alexander J.H., De Caterina R., Hanna M., Horowitz J.D., Hylek E.M., Lopes R.D., Asberg S., Granger C.B., Siegbahn A.; ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2014;130(21):1847–1858. doi:10.1161/CIRCULATIONAHA.114.011204.; Luan H.H., Wang A., Hilliard B.K., Carvalho F., Rosen C.E., Ahasic A.M., Herzog E.L., Kang I., Pisani M.A., Yu S., Zhang C., Ring A.M., Young L.H., Medzhitov R. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178(5):1231-1244. doi:10.1016/j.cell.2019.07.033.; Тишкова О.Г., Дикарева Л.В., Шварев Е.Г., Уханова Ю.Ю. Роль фактора дифференцировки роста-15 (GDF-15) в регуляции и развитии осложнений беременности. Астраханский медицинский журнал. 2022;17(1):14-22. doi:10.48612/agmu/2022.17.1.14.22.; Chow S.L., Maisel A.S., Anand I., Bozkurt B., de Boer R.A., Felker G.M., Fonarow G.C., Greenberg B., Januzzi J.L. Jr, Kiernan M.S., Liu P.P., Wang T.J., et al. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054-e1091. doi:10.1161/CIR.0000000000000490.; Unsicker K., Spittau B., Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev.2013;24 (4):373–384. doi:10.1016/j. cytogfr.2013.05.003.; Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425(6958):577–584. doi:10.1038/nature02006.; Kempf T., Eden M., Strelau J., Naguib M., Willenbockel C., Tongers J., Heineke J., Kotlarz D., Xu J., Molkentin J.D., Niessen H.W., Drexler H., Wollert K.C. The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res.2006;98(3):351–360. doi:10.1161/01.RES.0000202805.73038.48.; Bauskin A. R., Brown D. A., Junankar S., Rasiah K.K., Eggleton S., Hunter M., Liu T., Smith D., Kuffner T., Pankhurst G.J., Johnen H., Russell P.J., Barret W., Stricker P.D., Grygiel J.J., Kench J.G., Henshall S.M., Sutherland R.L., Breit S.N. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res. 2005;65(6):2330–2336. doi:10.1158/0008-5472.can-04-3827.; Ho F.M., Lin W.W., Chen B.C., Chao C.M., Yang C.R., Lin L.Y., Lai C.C., Liu S.H., Liau C.S. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006;18(3):391–399. doi:10.1016/j.cellsig.2005.05.009.; Li J., Yang L., Qin W., Zhang G., Yuan J., Wang F. Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus. PLoS ONE. 2013;8(6). doi:10.1371/journal.pone.0065549.e65549; Lok S. I., Winkens B., Goldschmeding R., van Geffen A.J., Nous F.M., van Kuik J., van der Weide P., Klöpping C., Kirkels J.H., Lahpor J.R., Doevendans P.A., de Jonge N., de Weger R.A. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012;14(11):1249–1256. doi:10.1093/eurjhf/hfs120.; Wang L., Wei X. Yang Zhong J. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc. 2019;8(17):e012826. doi:10.1161/JAHA.119.012826.; Rohatgi A., Patel P., Das S.R., Ayers C.R., Khera A., Martinez-Rumayor A., Berry J.D., McGuire D.K., de Lemos J.A. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas heart study. Clinical Chemistry. 2012;58(1):172–182. doi:0.1373clinchem.2011.171926.; Brown D.A., Breit S.N., Buring J., Fairlie W.D., Bauskin A.R., Liu T., Ridker P.M. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002;359(9324):2159–2163. doi:10.1016/s0140-6736(02)09093-1.; Daniels L.B., Clopton P., Laughlin G.A., Maisel A.S., Barrett-Connor E. Growth- differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation. 2011;123(19):2101–2110. doi:10.1161/CIRCULATIONAHA.110.979740.; Lind L., Wallentin L., Kempf T., Tapken H., Quint A., Lindahl B., Olofsson S., Venge P., Larsson A., Hulthe J., Elmgren A., Wollert K.C. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the prospective investigation of the vasculature in uppsala seniors (PIVUS) study. Eur Heart J.2009;30 (19):2346–2353. doi:10.1093/eurheartj/ehp261.; Bonaterra G.A., Struck N., Zuegel S., Schwarz A., Mey L., Schwarzbach H., Strelau J., Kinscherf R. Characterization of atherosclerotic plaques in blood vessels with low oxygenated blood and blood pressure (Pulmonary trunk): role of growth differentiation factor-15 (GDF-15). BMC Cardiovasc Disord. 2021;21(1):601. doi:10.1186/s12872-021-02420-9.; Сабирзянова А.А., Галявич А.С., Балеева Л.В., Галеева З.М. Фактор дифференцировки роста-15 у пациентов в острой стадии инфаркта миокарда. Кардиология. 2020;60(11):42-48. doi:10.18087/cardio.2020.11.n1251; Kempf T., Zarbock A., Widera C., Butz S., Stadtmann A., Rossaint J., Bolomini-Vittori M., Korf-Klingebiel M., Napp L.C., Hansen B., Kanwischer A., Bavendiek U., Beutel G., Hapke M., Sauer M.G., Laudanna C., Hogg N., Vestweber D., Wollert K.C. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nature Medicine. 2011;17 (5):581–588. doi:10.1038/nm.2354.; 2021 Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022;27(7):5155. doi:10.15829/1560-4071-2022-5155; S ̈okmen E., Uçar C., Sivri S., Çelik M., Boduroğlu Y., Erer M., Yıldırım A., İlanbey B. Association between growth differentiation factor 15 and non-dipping circadian pattern in patients with newly diagnosed essential hypertension. Med Princ Pract.2019;28 (6):566–572. doi:10.1159/000501096.; Lewis G. A., Rosala-Hallas A., Dodd S. Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone. J Am Heart Assoc.2022;11(14):e024668. doi:10.1161/JAHA.121.024668; Hillege H.L., Nitsch D., Pfeffer M.A., Swedberg K., McMurray J.J., Yusuf S., Granger C.B., Michelson E.L., Ostergren J., Cornel J.H., de Zeeuw D., Pocock S., van Veldhuisen D.J.; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113 (5):671–678. doi:10.1161/CIRCULATIONAHA.105.580506; Драпкина О. М., Палаткина Л. О. Маркеры цитокиновой активации и оксидативного стресса у больных хронической сердечной недостаточностью. Журнал сердечная недостаточность. 2013;14(6):341-346. doi:10.1007/s00392-021-01944-6.; Кривошеева Е.Н., Кропачева Е.С., Добровольский А.Б., Титаева Е.В., Панченко Е.П.Ростовой фактор дифференцировки-15 и риск сердечно-сосудистых осложнений у пациентов с фибрилляцией предсердий после планового чрескожного коронарного вмешательства. Российский кардиологический журнал. 2021;26(7):24-30. doi:10.15829/1560-4071-2021-4457; Hijazi Z., Oldgren J., Lindbäck J., Alexander J.H., Connolly S.J., Eikelboom J.W., Ezekowitz M.D., Held C., Hylek E.M., Lopes R.D., Siegbahn A., Yusuf S., Granger C.B., Wallentin L.; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. The Lancet. 2016;387(10035):2302-11. doi:10.1016/s0140- 6736(16)00741-8.; Berg D., Ruff C., Jarolim P., Giugliano R.P., Nordio F., Lanz H.J., Mercuri M.F., Antman E.M., Braunwald E., Morrow D.A. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI Circulation. 2019;139(6):760-71. doi:10.1161/circulationaha.118.038312.; Carstensen M., Herder C., Brunner E.J.S., Strassburger K., Tabak A.G., Roden M., Witte D.R. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol.2010;162(5):913–917. doi:10.1530/EJE-09-1066.; Dostalova I., Roubicek T., Bartlova M., Mráz M,, Lacinová Z,, Haluzíková D,, Kaválková P,, Matoulek M,, Kasalicky M,, Haluzík M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol.2009;161(3):397–404. doi:10.1530/EJE-09-0417.; Carlsson A.C., Nowak C., Lind L., Östgren C.J., Nyström F.H., Sundström J., Carrero J.J., Riserus U., Ingelsson E., Fall T., Ärnlöv J. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020;125 (1):37–43. doi:10.1080/03009734.2019.1696430.; Viola J., Soehnlein O. Atherosclerosis–a matter of unresolved inflammation. Seminars in immunology. Academic Press. 2015; 27(3):184-193.; Jeremias I., Kupatt C., Martin-Villalba A., Habazettl H., Schenkel J., Boekstegers P., Debatin K.M. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation. 2000;102:915–920. doi:10.1161/01.cir.102.8.915.; Kurrelmeyer K.M., Michael L.H., Baumgarten G., Taffet G.E., Peschon J.J., Sivasubramanian N., Entman M.L., Mann D.L. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A. 2000;97:5456 –5461. doi:10.1073/pnas.070036297.; Гуревич М. А. Артериальная гипертония и хроническая сердечная недостаточность-единство патогенеза и принципов лечения. Российский кардиологический журнал. 2005;6:91-95.; Wischhusen J., Melero I., Fridman W.H. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020 May 19;11:951. doi:10.3389/fimmu.2020.00951; Shimano M., Ouchi N., Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome.Circulation. 2012;126(21): e327-e332. doi:10.1161/CIRCULATIONAHA.112.150656; Babalghith A.O., Al-kuraishy H.M., Al-Gareeb A.I., De Waard M., Sabatier J.M., Saad H.M., Batiha G.E. The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not? Diagnostics. 2022;12(9):2051. doi:10.3390/diagnostics12092051; Iglesias P., Silvestre R.A., Díez J.J. Growth differentiation factor 15 (GDF-15) in endocrinology. Endocrine. 2023; 81:419–431. doi.: 10.1007/s12020-023-03377-9; Al-Kuraishy H.M., Al-Gareeb A.I., Alblihed M., Cruz-Martins N., Batiha G.E. COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: the anti-inflammatory role of metformin. Front Med (Lausanne). 2021;8:110. doi:10.3389/fmed.2021.644295.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/1295
https://doi.org/10.17802/2306-1278-2023-12-3-211-219

Сравнительный анализ генетических факторов риска гипертонии и сердечно-сосудистых заболеваний у пациентов с изолированной артериальной гипертензией и пациентов с ассоциированными сердечно-сосудистыми событиями ; Comparative analysis of genetic risk factors for hypertension and cardiovascular diseases in patients with isolated arterial hypertension and patients with associated cardiovascular complications

Συγγραφείς: Deminа, N. R., Vesnina, N. S., Vishneva, E. M., Демина, Н. Р., Веснина, Н. С., Вишнева, Е. М.

Πηγή: Сборник статей

Θεματικοί όροι: HYPERTENSION, CARDIOVASCULAR EVENTS, GENETIC ANALYSIS, АГ, СЕРДЕЧНО-СОСУДИСТЫЕ СОБЫТИЯ, ГЕНЕТИЧЕСКИЙ АНАЛИЗ

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/7440

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7440

The importance of three-stage cardiac rehabilitation in patients with acute coronary syndrome and type 2 diabetes mellitus ; Значение трехэтапной кардиореабилитации у пациентов с острым коронарным синдромом и сахарным диабетом 2-го типа

Συγγραφείς: E. A. Nikitina, E. N. Chicherina, O. S. Elsukova, I. S. Metelev, Е. А. Никитина, Е. Н. Чичерина, О. С. Елсукова, И. С. Метелев

Πηγή: Meditsinskiy sovet = Medical Council; № 11 (2020); 12-18 ; Медицинский Совет; № 11 (2020); 12-18 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: прогноз, acute coronary syndrome, cardiac rehabilitation, cardiovascular events, prognosis, острый коронарный синдром, кардиореабилитация, неблагоприятные сердечно-сосудистые события

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5748/5246; Аронов Д.М., Козлова Л.В., Бубнова М.Г. Современное состояние и проблемы кардиореабилитации в России. CardioСоматика. 2017;8(3):5–9. Режим доступа: https://cardiosomatics.orscience.ru/archive/2017/tom-8-3-2017/sovremennoe-sostoyanie-i-problemy-kardioreabilitatsii-v-rossii_1083/?element.; Аронов Д.М., Бубнова М.Г. Проблемы внедрения новой системы кардиореабилитации в России. Российский кардиологический журнал. 2013;(4):14–22. doi:10.15829/1560-4071-2013-4-14-22.; Koskinas K.C., Siontis G.C., Piccolo R., Franzone A., Haynes A., Rat-Wirtzler J. et al. Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. Circ Cardiovasc Intery. 2016;9(2):1–11. doi:10.1161/CIRCINTERVENTIONS.115.003255.; Володина К.А., Линчак Р.М., Ачкасов Е.Е., Алаева Е.Н., Руненко С.Д., Курбакова Е.В. История кардиореабилитации: от строго 2-месячного постельного режима до скандинавской ходьбы. Кардиоваскулярная терапия и профилактика. 2017;16(4):100–105. doi:10.15829/1728-8800-2017-4-100-105.; McMahon S.R., Ades P.A., Thompson P.D. The role of cardiac rehabilitation in patients with heart disease. Trends Cardiovasc Med. 2017;27(6):420–425. doi:10.1016/j.tcm.2017.02.005.; Мисюра О.Ф., Шестаков В.Н., Зобенко И.А., Карпухин А.В., Александров П.В., Горюнова А.А. Организационные основы кардиореабилитации. Кардиосоматика. 2018;9(4):11–16. doi:10.26442/22217185.2018.4.000012.; Anderson L., Oldridge N., Thompson D.R., Zwisler A.D., Rees K., Martin N., Taylor R.S. Exercise-based cardiac rehabilitation for coronary heart disease. Am Coll Cardiol. 2016;67(1):1–12. doi:10.1016/j.jacc.2015.10.044.; Piepoli M.F., Corrà U., Adamopoulos S., Benzer W., Bjarnason-Wehrens B., Cupples M. et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European association for cardiovascular prevention & rehabilitation. endorsed by the committee for practice guidelines of the european society of cardiology. Eur J Prev Cardiol. 2014;21(6):664–681. doi:10.1177/2047487312449597.; Дедов И.И., Шестакова М.В., Викулова О.К., Исаков М.А., Железнякова А.В. Атлас регистра сахарного диабета Российской Федерации. Статус 2018 г. Сахарный диабет. 2019;22(S2–2):4–61. Режим доступа: https://elibrary.ru/item.asp?id=41436743.; Lettino M., Andell P., Zeymer U., Widimsky P., Danchin N., Bardaji A. et al. Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. Eur Heart J Cardiovasc Pharmacother. 2017;3(4):198–213. doi:10.1093/ehjcvp/pvw049.; Zhou M., Liu J., Hao Y., Liu J., Huo Y., Smith S.C. Jr. et al. Prevalence and inhospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Cardiovasc Diabetol. 2018;17(1):147. doi:10.1186/s12933-018-0793-x.; Ramanathan K., Abel J.G., Park J.E., Fung A., Mathew V., Taylor C.M. et al. Surgical versus percutaneous coronary revascularization in patients with diabetes and acute coronary syndromes. J Am Coll Cardiol. 2017;70(24):2995–3006. doi:10.1016/j.jacc.2017.10.029.; Foussas S.G. Acute coronary syndromes and diabetes mellitus. Hellenic J Cardiol. 2016;57(5):375–377. doi:10.1016/j.hjc.2016.12.012.; Hammoudeh A.J., Tabbalat R., Alhaddad I.A., Khader Y., Jarrah M., Izraiq M., Al-Mousa E. Short- and long-term outcomes in middle eastern diabetic patients after percutaneous coronary intervention: results from the first jordanian pci registry (JOPCR1). Diabetol Int. 2016;8(1):30–38. doi:10.1007/s13340-016-0273-z.; Ruano-Ravina A., Pena-Gil C., Abu-Assi E., Raposeiras S., Hof A., Meindersma E. et al. Participation and adherence to cardiac rehabilitation programs. A Systematic Review. Int J Cardiol. 2016;223:436–443. doi:10.1016/j.ijcard.2016.08.120.; Foster J.G., Lewis S.F., Hennekens C.H. Editorial Commentary: Cardiac Rehabilitation: Major Benefits and Minor Risks. Trends Cardiovasc Med. 2017;27(6):426–427. doi:10.1016/j.tcm.2017.03.001.; Simon M., Korn K., Cho L., Blackburn G.G., Raymond C. Cardiac rehabilitation: a class 1 recommendation. Cleve Clin J Med. 2018;85(7):551–558. doi:10.3949/ccjm.85a.17037.; Powell R., McGregor G., Ennis S., Kimani P.K., Underwood M. Is exercise-based cardiac rehabilitation effective? A systematic review and meta-analysis to re-examine the evidence. BMJ Open. 2018;8(3):1–14. doi:10.1136/bmjopen-2017-019656.; Kotseva K., Wood D., Bacquer D. EUROASPIRE investigators. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV Survey. Eur J Prev Cardiol. 2018;25(15):1242–1251. doi:10.1177/2047487318781359.; Kasperowicz A., Cymerys M., Kasperowicz T. Effectiveness of cardiac rehabilitation in exercise capacity increase in patients with ST-segment elevation myocardial infarction. Int J Environ Res Public Health. 2019;16(21):4085. doi:10.3390/ijerph16214085.; Бубнова М.Г., Барбараш О.Л., Долецкий А.А., Красницкий В.Б., Лебедева Е.В., Лямина Н.П. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы: реабилитация и вторичная профилактика. Российский кардиологический журнал. 2015;(1):6–52. doi:10.15829/1560-4071-2015-1-6-52.; Urbinati S., Tonet E. Cardiac rehabilitation after STEMI. Minerva Cardioangiol. 2018;66(4):464–470. doi:10.23736/S0026-4725.18.04674-1.; Эрлих А.Д., Грацианский Н.А. Острый коронарный синдром у больных сахарным диабетом: реальная практика российских стационаров (по результатам регистра RECORD). Сахарный диабет. 2012;15(2):27–31. doi:10.14341/2072-0351-5515.; Choe Y. Han J.Y., Choi I.S., Park H.K. Improvement of exercise capacity in patients with type 2 diabetes mellitus during cardiac rehabilitation. Eur J Phys Rehabil Med. 2018;56(4):981–983. doi:10.23736/S1973-9087.18.05250-4.; Reibis R., Tresz A., Bestehorn K., Karoff M., Schwaab B., Wirth A. et al. Comparable short-term prognosis in diabetic and non-diabetic patients with acute coronary syndrome after cardiac rehabilitation. Eur J Prev Cardiol. 2012;19(1):15–22. doi:10.1177/1741826710393993.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/5748
https://doi.org/10.21518/2079-701X-2020-11-12-18

Relationship between immunological alterations, hypoxia and inflammation in arterial hypertension combined with metabolic syndrome ; Взаимосвязь иммунологических нарушений, гипоксии и воспаления при артериальной гипертензии и метаболическом синдроме

Συγγραφείς: E. I. Polozova, E. V. Puzanova, A. A. Seskina, Э. И. Полозова, Е. В. Пузанова, А. А. Сеськина

Πηγή: Medical Immunology (Russia); Том 22, № 5 (2020); 1003-1008 ; Медицинская иммунология; Том 22, № 5 (2020); 1003-1008 ; 2313-741X ; 1563-0625

Θεματικοί όροι: сердечно-сосудистые события, metabolic syndrome, pathogenesis, cytokine imbalance, hypoxia, non-specific inflammation, cardiovascular events, метаболический синдром, патогенез, цитокиновый дисбаланс, гипоксия, неспецифическое воспаление

Περιγραφή αρχείου: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2059/1319; Boytsov S.A., Balanova Yu.A., Shalnova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M., Duplyakov D.V., Efanov A.Yu., Zhernakova Yu.V., Konradi A.O., Libis R.A., Minakov A.V., Nedogoda S.V., Oshchepkova E.V., Romanchuk S.A., Rotar O.P., Trubacheva I.A., Chazova I.E., Shlyakhto E.V., Muromtseva G.A., Evstifeeva S.E., Kapustina A.V., Konstantinov V.V., Oganov R.G., Mamedov M.N., Baranova E.I., Nazarova O.A., Shutemova O.A., Furmenko G.I., Babenko N.I., Azarin O.G., Bondartsov L.V., Khvostikova A.E., Ledyaeva A.A., Chumachek E.V., Isaeva E.N., Basyrova I.R., Kondratenko V.Yu., Lopina E.A., Safonova D.V., Skripchenko A.E., Indukaeva E.V., Cherkass N.V., Maksimov S.A., Danilchenko Y.V., Mulerova T.A., Shalaev S.V., Medvedeva I.V., Shava V.G., Storozhok M.A., Tolparov G.V., Astakhova Z.T., Toguzova Z.A., Kaveshnikov V.S., Karpov R.S., Serebryakova V.N. Arterial hypertension in subjects aged 25-64 years: prevalence, awareness, treatment and control. Based on ESSAY study data. Cardiovascular Therapy and Prevention, 2014, Vol. 13, no. 4, pp. 4-14. (In Russ.); Bulaeva N.I., Golukhova E.Z. Endothelial dysfunction and oxidative stress: a role in developing cardiovascular pathology. Creative Cardiology, 2013, no. 1, pp. 14-22. (In Russ.); Clinical recommendations. Arterial hypertension in adulthood (Electronic resourсe). Russian Society of Cardiology. Approved year: 2020. Access mode: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf.; Markov Kh.M. Molecular mechanisms of dysfunctional vascular endothelium. Cardiology, 2005, no. 12, pp. 62-67. (In Russ.); Polozova E.I., Puzanova E.V., Seskina A.A. A role of immunological alterations, endothelial dysfunction and hemostatic disturbances in generation of arterial hypertension in metabolic syndrome. Medical Immunology (Russia), 2020, Vol. 22, no. 2, pp. 221-230. (In Russ.) doi:10.15789/1563-0625-ROI-1926.; Prevalence of risk factors for non-infectious diseases in 2012-2013 Russia-wide population. ESSAY study data. Cardiovascular Therapy and Prevention, 2014, Vol. 13, no. 6, pp. 4-11. (In Russ.); Sergeeva V.V., Rodionova A.Yu. Contemporary approach to assess arterial hypertension combined with metabolic disturbances. Arterial Hypertension, 2013, Vol. 19, no. 5, pp. 397-404. (In Russ.); Sumerkina V.A., Chulkov Vl.S., Chulkov V.S., Ozhigina E.V. Status of hemostasis system and cytokine profile in patients with metabolic syndrome (in Russian). Kazan Medical Journal, 2015, Vol. 96, no. 5, pp. 728-734. (In Russ.); Timasheva Ya.R. Immunological aspects of essential hypertension. Medical immunology (Russia), 2019, Vol. 21, no. 3, pp. 407-418. (In Russ.); Chukaeva I.I., Orlova N.V., Khavka N.N., Klepikova M.V. Examining inflammatory factors in patients with metabolic syndrome. Metabolic Syndrome. Medicine, 2010, Vol. 4, pp. 50-56. (In Russ.); Caillon A., Schiffrin E.L. Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence. Curr. Hypertens. Rep., 2016, Vol. 18, no. 3, 21. doi:10.1007/s11906-016-0628-7.; Ehret G.B., Caulfield M.J. Genes for blood pressure: an opportunity to understand hypertension. Eur. Heart J., 2013, Vol. 34, pp. 951-961.; Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J., 2018, Vol. 39, Iss. 33, pp. 3021-3104.; https://www.mimmun.ru/mimmun/article/view/2059

Διαθεσιμότητα: https://www.mimmun.ru/mimmun/article/view/2059
https://doi.org/10.15789/1563-0625-RBI-2059

The manifestation of obesity paradox in patients with myocardial infarction and various systolic dysfunctions: Myth or reality? ; Проявления парадокса ожирения у пациентов с инфарктом миокарда в зависимости от тяжести систолической дисфункции миокарда: миф или реальность?

Συγγραφείς: D. Yu. Sedykh, A. I. German, O. N. Khryachkova, V. V. Kashtalap, O. L. Barbarash, Д. Ю. Седых, А. И. Герман, О. Н. Хрячкова, В. В. Кашталап, О. Л. Барбараш

Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 35, № 2 (2020); 56-65 ; Сибирский журнал клинической и экспериментальной медицины; Том 35, № 2 (2020); 56-65 ; 2713-265X ; 2713-2927 ; 10.29001/2073-8552-2020-35-2

Θεματικοί όροι: смерть, prognosis, obesity, body mass index, left ventricular ejection fraction, recurrent cardiovascular event, death, прогноз, общее ожирение, индекс массы тела, фракция выброса левого желудочка, повторные сердечно-сосудистые события

Περιγραφή αρχείου: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/975/531; World Health Organization – WHO (2017). Obesity and overweight. Controlling the global obesity epidemic. URL: http://www.who.int/nutrition/topics/obesity/en (access date: 23.12.2019).; Fursov R., Ospanov O., Fursov A. Prevalence of obesity in Kazakhstan. AMJ. 2017;10(11):916–920. DOI:10.21767/AMJ.2017.3169.; NIDDK/NIH (National Institute of Diabetes and Digestive and Kidney Diseases). URL: https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity (access date: 22.12.2019).; Kitahara C.M., Flint A.J., de Gonzalez A.B., Bernstein L., Brotzman M., MacInnis R.J. et al. Association between class III obesity (BMI of 40–59 kg/m2 ) and mortality: a pooled analysis of 20 prospective studies. PLoS Med. 2014;11(7):e1001673. DOI:10.1371/journal.pmed.1001673.; Reeves G.K., Pirie К., Beral V., Green J., Spencer E., Bull D. et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134. DOI:10.1136/bmj.39367.495995.AE.; Manson J.E., Willett W.C., Stampfer M.J., Colditz G.A., Hunter D.J., Hankinson S.E. et al. Body weight and mortality among women. N. Engl. J. Med. 1995;333(11):677–685. DOI:10.1056/NEJM199509143331101.; McNamee D. Extreme obesity linked to substantially higher death rates. Medical News Today. URL: https://www.medicalnewstoday.com/articles/279337.php (access date: 30.12.2019).; Fitzgerald К., Even A. Few еxtra рounds сan be dangerous to your heart. Medical News Today. URL: https://www.medicalnewstoday.com/articles/262542.php?sr (access date: 27.12.2019).; Lee S.H., Tak Y.J., Yi Y.H., Lee S.Y., Cho Y.H., Lee J.G. et al. Correlations between obesity indices and cardiometabolic risk factors in obese subgroups in women with severe obesity: A multicenter, cross-sectional study. Obesity Research and Clinical Practice (ORCP). 2017;11(2):167– 176. DOI:10.1016/j.orcp.2016.03.014.; Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003;348:1625–1638. DOI:10.1056/NEJMoa021423.; Song M., Hu F.B., Wu K., Must A., Chan A.T., Willett W.C. et al. Trajectory of body shape in early and middle life and all cause and cause specific mortality: results from two prospective US cohort studies. BMJ. 2016;353:i2195. DOI:10.1136/bmj.i2195.; Wise J. Waist measurement, not BMI, is stronger predictor of death risk, study finds. BMJ. 2017;357:j2033. DOI:10.1136/bmj.j2033.; Padwal R.S., Pajewski N.M., Allison D.B., Sharma A.M. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):E1059–1066. DOI:10.1503/cmaj.110387.; Драпкина О.М., Шепель Р.Н. Хроническая сердечная недостаточность и «парадокс ожирения». Журнал Сердечная Недостаточность. 2016;17(6):398–404. DOI:10.18087/rhfj.2016.6.2263.; Mosterd A. The prognosis of heart failure in the general population: The Rotterdam Study. Eur. Heart J. 2001;22(15):1318–1327. DOI:10.1053/euhj.2000.2533.; Sharma A., Vallakati A., Einstein A.J., Lavie C.J., Arbab-Zadeh A., Lopez-Jimenez F. et al. Relationship of Body Mass Index with Total Mortality, Cardiovascular Mortality, and Myocardial Infarction after Coronary Revascularization: Evidence from a Meta-analysis. Mayo Clin. Proc. 2014;89(8):1080–1100. DOI:10.1016/j.mayocp.2014.04.020.; Fonarow G.C., Srikanthan P., Costanzo M.R., Cintron G.B., Lopatin M. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am. Heart J. 2007;153(1):74–81. DOI:10.1016/j.ahj.2006.09.007.; Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur. Heart J. 2012;33:1750–1757.; Lavie C.J., de Schutter A., Patel D., Artham S.M., Milani R.V. et al. Body сomposition and сoronary heart disease mortality – an obesity or a lean paradox? Mayo Clin. Proc. 2011;86(9):857–864. DOI:10.4065/mcp.2011.0092.; Padwal R., McAlister F.A., McMurray J.J., Cowie M.R., Rich M., Pocock S. et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int. J. Obes. (Lond). 2014;38(8):1110–1114. DOI:10.1038/ijo.2013.203.; Barth S., Zacher М., Reinecke Н., Hautmann M.B., Kerber S., Gietzen F. et al. Decreasing incidence of coronary heart disease in extreme obesity (BMI ≥ 40) – а single centre experience. Obes. Res. Clin. Pract. 2017;11(4):435–444. DOI:10.1016/j.orcp.2016.08.007.; Kalantar-Zadeh К., Rhee С.М., Alpesh A.N. To legitimize the contentious obesity paradox. Mayo Clin. Proc. 2014;89(8):1033–1035. DOI:10.1016/j.mayocp.2014.06.015.; Stokes А., Ni Y., Preston S.H. Prevalence and trends in lifetime obesity in the U.S., 1988–2014. Am. J. Prev. Med. 2017;53(5):567–575. DOI:10.1016/j.amepre.2017.06.008.; Авдеева К.С., Петелина Т.И., Гапон Л.И., Мусихина Н.А., Зуева Е.В. Особенности артериальной гипертонии у женщин с абдоминальным ожирением в постменопаузе: роль маркеров воспалительной реакции, лептина и женских половых гормонов в патогенезе ригидности сосудистой стенки. Сибирский медицинский журнал. 2019;34(3):103–113. DOI:10.29001/2073-8552-2019-34-3-103-113.; Герман А.И., Федорова Н.В., Печерина Т.Б., Чернобай А.Г., Груздева О.В., Каретникова В.Н. и др. Влияние ожирения на клиническое течение инфаркта миокарда. РМЖ. Медицинское обозрение. 2019;1(II):70–75.; Отт А.В., Чумакова Г.А. Эпикардиальное ожирение как один из основных критериев метаболически тучного фенотипа ожирения и предикторов субклинического атеросклероза. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):21–28. DOI:10.17802/2306-1278-2018-7-1-21-28.; https://www.sibjcem.ru/jour/article/view/975

Διαθεσιμότητα: https://www.sibjcem.ru/jour/article/view/975
https://doi.org/10.29001/2073-8552-2020-35-2-56-65

Cardiovascular safety in the treatment of diabetes mellitus type 2: focus on alogliptin

Συγγραφείς: A. L. Terekhova, N. A. Petunina

Πηγή: Медицинский совет, Vol 0, Iss 3, Pp 38-47 (2016)

Θεματικοί όροι: safety, ингибиторы дпп-4, efficacy, эффективность, сердечно-сосудистые события, alogliptin, безопасность, 3. Good health, cardiovascular events, hypoglycemia, dpp-4 inhibitors, Medicine, випидия, vipidiya, алоглиптин, гипогликемия

Σύνδεσμος πρόσβασης: https://www.med-sovet.pro/jour/article/download/57/57
https://doaj.org/article/f59db13f05d5447f9f4a9f112942e995
http://www.med-sovet.pro/jour/article/view/57
https://www.med-sovet.pro/jour/article/download/57/57
https://cyberleninka.ru/article/n/kardiovaskulyarnaya-bezopasnost-v-terapii-saharnogo-diabeta-2-go-tipa-fokus-na-alogliptin/pdf
https://cyberleninka.ru/article/n/kardiovaskulyarnaya-bezopasnost-v-terapii-saharnogo-diabeta-2-go-tipa-fokus-na-alogliptin

Сучасні аспекти лікування гіпертонічної хвороби, поєднаної з ішемічною хворобою серця

Συγγραφείς: Bondarchuk, S. A., Andrievsky, О. G.

Πηγή: Medicine of Ukraine; № 1(237) (2020); 28-32
Лекарства Украины; № 1(237) (2020); 28-32
Ліки України; № 1(237) (2020); 28-32

Θεματικοί όροι: coronary artery disease, antihypertensives, target blood pressure, J-curve phenomenon, major adverse cardiovascular events, УДК 616.12–005.4–02:616.12–008.331.1–0.8, ишемическая болезнь сердца, гипертоническая болезнь, антигипертензивные средства, целеве артериальное давление, феномен J-кривой, неблагоприятные сердечно-сосудистые события, конечные точки, ішемічна хвороба серця, гіпертонічна хвороба, антигіпертензивні засоби, цільовий артеріальний тиск, феномен J-кривої, несприятливі серцево-судинні події, кінцеві точки, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/214171

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial ; Ингибиторы PCSK9 в улучшении прогноза у пациентов после острого коронарного синдрома: данные исследования ODYSSEY OUTCOMES

Συγγραφείς: Yu. Karpov A., Ю. Карпов А.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 14, No 6 (2018); 922-934 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 6 (2018); 922-934 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-6

Θεματικοί όροι: alirocumab, PCSK9 inhibitors, lipid-lowering treatment, hypercholesterolemia, acute coronary syndrome, major adverse cardiovascular events, алирокумаб, ингибиторы PCSK9, липидснижающая терапия, гиперхолестеринемия, острый коронарный синдром, большие неблагоприятные сердечно-сосудистые события

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1810/1753; Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. doi:10.1093/eurheartj/ehx144.; Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.Eur Heart J 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272; Jernberg T., Hasvold P., Henriksson M., et al. Cardiovascular risk in post-myocardial infarction patients: nationwide realworld data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163-70. doi:10.1093/eurheartj/ehu505.; Abu-Assi E., López-López A., González-Salvado V., et al. The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Esp Cardiol (Engl Ed). 2016;69(1):11-18. doi:10.1016/j.rec.2015.06.015.; Stone G.W., Maehara A., Lansky A.J., et al. A Prospective Natural-History Study of Coronary Atherosclerosis. N Engl J Med 2011;364(3):226-235. doi:10.1056/NEJMoa1002358.; Maron D.J., Spertus, J.A., ManciniG.B., et al. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol. 2009;104(8):1055-62. doi:10.1016/j.amjcard.2009.05.056.; Jellinger P.S., Handelsman Y., Rosenblit P.D, et al. American Association of Clinical Endocrinologists and American Collegeof Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1-87. doi:10.4158/EP171764.APPGL.; Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и Дислипидемии. 2017;3:5-22; Zhao S., Wang Y., Mu Y., et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014; 235(2):463-9.doi:10.1016/j.atherosclerosis.2014.05.916; Reiner, Ž. De Backer G., Fras Z., et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243-50. doi:10.1016/j.atherosclerosis.2016.01.018.; Kotseva K. on behalf of EUROASPIRE investigators. Implementation of cardiovascular disease prevention in daily practice – Insights from EUROASPIRE V. Reaching lipid targets in coronary patents -Temporal trends and state of the art. Presented at ESC 2018, Munich. [cited by Nov 11, 2018]. Available from: https://esc365.escardio.org/Congress/ESC-Congress-2018/Implementation-of-cardiovascular-disease-prevention-in-daily-practice-Insig/174542-reaching-lipid-targets-in-coronarypatents-temporal-trends-and-state-of-the-art#slide.; Gitt A.K., Drexel H., Feely J., et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prevent Cardiol. 2012;19:221-30. doi:10.1177/1741826711400545.; Nanchen D., Gencer B., Auer R., et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J. 2015;36(36):2438-45. doi:10.1093/eurheartj/ehv289.; Benn M., Watts G.F., Tybjaerg-Hansen A., et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956-64.; Ежов М.В., Лазарева Н.В., Сагайдак О. В. и др. Частота нарушений липидного обмена и применение статинов при остром коронарном синдроме (по данным Федерального Регистра острого коронарного синдрома). Атеросклероз и Дислипидемии. 2018;1:47-57; Rallidis L.S., Triantafyllis A.S., Tsirebolos G., et al. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins Atherosclerosis. 2016;249:17-21. doi:10.1016/j.atherosclerosis.2016.03.023.; Zhang H., Plutzky J., Skentzos S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526-34. doi:10.7326/0003-4819-158-7-201304020-00004.; Ganga H.V., Slim H.B., Thompson P.D. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6-15.doi:10.1016/j.ahj.2014.03.019.; Cohen J.D., Brinton E.A., Ito M.K., et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208-15. doi:10.1016/j.jacl.2012.03.003.; Serban M.C., Colantonio L.D., Manthripragada A.D., et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017;69(11):1386-95. doi:10.1016/j.jacc.2016.12.036.; Инструкция по медицинскому применению лекарственного препарата Пралуэнт, раствор для подкожного введения, 75 или 150 мг/мл, РУ № ЛП-004078 (АО «Санофи-Авентис груп», Франция). [цитировано 10.11.2018]. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=72fb3609-34cf-40e6-b158-50d388a4d0d8&t=; McKenney J.M., Koren M.J., Kereiakes D.J., et al. Safety and efficacy of a monoclonal antibody to proproteinconvertasesubtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344-53. doi:10.1016/j.jacc.2012.03.007.; Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012; 380(9836):29-36. doi:10.1016/S0140-6736(12)60771-5.; Roth E.M., Taskinen M.R., Ginsberg H.N., et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176(1):55-61. doi:10.1016/j.ijcard.2014.06.049.; Moriarty P.M., Thompson P.D., Cannon C.P., et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-69. doi:10.1016/j.jacl.2015.08.006.; Stroes E., Guyton J.R., Farnier M., et al. for the ODYSSEY CHOICE II investigators. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016;5(9):e003421. doi:10.1161/JAHA.116.003421.; Teramoto T., Kobayashi M., Uno K., et al. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies). Am J Cardiol. 2016;118(1):56-63. doi:10.1016/j.amjcard.2016.04.011.; Kastelein J.J., Ginsberg H.N., Langslet G., et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003. doi:10.1093/eurheartj/ehv370.; Ginsberg H.N., Rader D.J., Raal F.J., et al. Efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Cardiovasc Drugs Ther. 2016;30(5):473-83. doi:10.1007/s10557-016-6685-y.; Robinson J.G., Farnier M., Krempf M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-99. doi:10.1056/NEJMoa1501031.; Kereiakes D.J., Robinson J.G., Cannon C.P., et al. Efficacy and safety of the proproteinconvertasesubtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-915.e13. doi:10.1016/j.ahj.2015.03.004.; Cannon C.P., Cariou B., Blom D., et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186-94. doi:10.1093/eurheartj/ehv028.; Bays H., Gaudet D., Weiss R., et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140-8. doi:10.1210/jc.2015-1520.; Farnier M., Jones P., Severance R., et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138-46. doi:10.1016/j.atherosclerosis.2015.11.010.; Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107. doi:10.1056/NEJMoa1801174.; Schwartz G.G. Szarek M.M., Bhatt D.L., et al. Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment. Presentation at American Heart Association Scientific Session (November 11, 2018), Chicago (Illinois), USA. [cited by Nov 10, 2018]. Available from: http://abstractsonline.com/pp8/#!/ 4682/presentation/59973.; Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97.doi:10.1056/NEJMoa1410489.; Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-99. doi:10.1056/NEJMoa1206797.; Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in patients treated with alirocumab. N Engl J Med. 2017;376:1589-90.; Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. doi:10.1056/NEJMoa040583.; Navarese E.P., Robinson J.G., Kowalewski M., et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319:1566-79. doi:10.1001/jama.2018.2525.; Sabatine M.S., Giugliaano R.P., Keech A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22. doi:10.1056/NEJMoa1615664.; Ridker P.M., Revkin J., Amarenco P., et al. Cardiovascular efficacy and safety of bococizumab in highrisk patients. N Engl J Med. 2017;376:1527-39. doi:10.1056/NEJMoa1701488.; https://www.rpcardio.com/jour/article/view/1810

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/1810
https://doi.org/10.20996/1819-6446-2018-14-6-922-934

Hormonal contraceptives and the risk of ischemic stroke in women with migraine: a new international consensus ; Гормональные контрацептивы и риск ишемического инсульта у женщин с мигренью: новый международный консенсус

Συγγραφείς: E. V. Ekusheva, M. I. Karpova, V. V. Osipova, Е. В. Екушева, М. И. Карпова, В. В. Осипова

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 3 (2019); 11-15 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 3 (2019); 11-15 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-3

Θεματικοί όροι: риск ишемического инсульта, migraine with aura, hormonal contraception, cardiovascular events, risk of ischemic stroke, мигрень с аурой, гормональная контрацепция, сердечно-сосудистые события

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1167/922; Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2017;390:1211-1859. doi:10.1016/S0140-6736 (17)32154-2; Tietjen GE, Collins SA. Hypercoagulability and migraine. Headache. 2018;58(1):173-183. http://dx.doi.org/10.1111/head.13044; Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81. doi:10.1177/0333102412438977. Epub 2012 Mar 6.; Осипова ВВ, Табеева ГР. Первичные головные боли: диагностика, клиника, терапия: практическое руководство. Москва: МИА; 2014. 336 с.; Екушева ЕВ. Оптимальные подходы к купированию приступа мигрени: прошлое, настоящее и будущее. Русский медицинский журнал. 2012;(10):522-8.; Finocchi C, Strada L. Sex-related differences in migraine. Neurol Sci. 2014 May;35 Suppl 1:207-13. doi:10.1007/s10072-014-1772-y.; Buse DC, Reed ML, Fanning KM, et al. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017 Jan;57(1):31-44. doi:10.1111/head.12962. Epub 2016 Nov 12.; Peng KP, Chen YT, Fuh JL, et al. Migraine and incidence of ischemic stroke: A nationwide population-based study. Cephalalgia. 2017 Apr; 37(4):327-335. doi:10.1177/0333102416642602. Epub 2016 Apr 26.; Sacco S, Ricci S, Carolei A. Migraine and vascular diseases: a review of the evidence and potential implications for management. Cephalalgia. 2012 Jul;32(10):785-95. doi:10.1177/0333102412451361. Epub 2012 Jun 18.; Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian national research council study group on stroke in the young. Lancet. 1996 Jun 1;347(9014):1503-6.; Nicodemo M, Cevoli S, Giannini G, Cortelli P. Comorbidity in perimenstrual migraine. Curr Pain Headache Rep. 2012 Oct;16(5):477-83. doi:10.1007/s11916-012-0281-z.; Todd C, Lagman-Bartolome AM, Lay C. Women and migraine: the role of hormones. Curr Neurol Neurosci Rep. 2018 May 31;18(7): 42. doi:10.1007/s11910-018-0845-3.; Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache. 2018 Jan;58(1):5-21. doi:10.1111/head.13229. Epub 2017 Nov 15.; Vetvik KG, Benth JS, MacGregor EA, et al. Menstrual versus non-menstrual attacks of migraine without aura in women with and without menstrual migraine. Cephalalgia. 2015 Dec; 35(14):1261-8. doi:10.1177/0333102415575723. Epub 2015 Mar 9.; Elliott D, Li X, Zhu P, Gaitour E. Headache in pregnancy. In: Minagar A, editor. Neurological Disorders and Pregnancy. London: Elsevier; 2011. P. 19-37.; Medical eligibility criteria for contraceptive use, 5th ed. Geneva: WHO; 2015. 276 p.; Sacco S, Merki-Feld GS, AEgidius KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017 Oct 30;18(1):108. doi:10.1186/s10194-017-0815-1.; Abanoz Y, Abanoz YG, Gü ndü z A, et al. Migraine as a risk factor for young patients with ischemic stroke: a case-control study. NNeurol Sci. 2017 Apr;38(4):611-617. doi:10.1007/s10072-017-2810-3. Epub 2017 Jan 12.; The Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception. 2003 Mar; 67(3):173-85.; Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000 Jul 5;284(1):72-8.; Calhoun A, Ford S, Pruitt A. The impact of the extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. Headache. 2012 Sep;52(8):1246-53. doi:10.1111/j.1526-4610.2012.02211.x. Epub 2012 Jul 12.; Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007 Jan;47(1):27-37. doi:10.1111/j.1526-4610.2007.00650.x; Nappi RE, Kaunitz AM, Britzer J. Extended regimen combined oral contraception: a review of evolving concepts and acceptance by woman and clinicians. Eur J Contracept Reprod Health Care. 2016;21(2):106-15. doi:10.3109/13625187.2015.1107894. Epub 2015 Nov 17.; Collaborative group. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015 Sep;16(9): 1061-1070. doi:10.1016/S1470-2045(15)00212-0. Epub 2015 Aug 4.; Collaborative group. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet. 2008 Jan 26;371(9609):303-14. doi:10.1016/S0140-6736(08)60167-1.; Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003 Aug 12;61(3):375-82. doi:10.1212/01.WNL.0000078940.53438.83; Eriksen MK, Thomsen LL, Olesen J. The visual aura rating scala (VARS) for migraine aura diagnosis. Cephalalgia. 2005 Oct; 25(10):801-10. doi:10.1111/j.1468-2982.2005.00955.x

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1167
https://doi.org/10.14412/2074-2711-2019-3-11-15

Perioperative assessment of troponin level in the non-cardiac interventions: is there such a need?

Συγγραφείς: Array N. Sumin

Πηγή: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 5, Pp 529-534 (2015)

Θεματικοί όροι: non-cardiac surgery, сердечно-сосудистые события, RM1-950, некардиальные операции, 3. Good health, cardiovascular events, troponin screening, 03 medical and health sciences, 0302 clinical medicine, RC666-701, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology, скрининг, тропонин

Σύνδεσμος πρόσβασης: https://www.rpcardio.com/jour/article/download/328/346
https://doaj.org/article/d80ddf3de56240fea2b09b3a345a939c
https://doaj.org/article/b700cb195d5342caa98d59e77e3ddf96
https://www.rpcardio.com/jour/article/download/328/346
https://www.rpcardio.com/jour/article/view/328
https://core.ac.uk/display/87816466
https://doaj.org/article/b700cb195d5342caa98d59e77e3ddf96

ANDROGEN DEFICIENCY IN AGING MALE AND ISCHEMIC HEART DISEASE

Πηγή: ВЕСТНИК ОБРАЗОВАНИЯ И РАЗВИТИЯ НАУКИ РОССИЙСКОЙ АКАДЕМИИ ЕСТЕСТВЕННЫХ НАУК.

Θεματικοί όροι: myocardial revasculization, ишемическая болезнь сердца, сердечно-сосудистые события, age-dependent androgen deficiency, total testosterone, ischemic heart disease, 3. Good health, 03 medical and health sciences, cardiovascular events, 0302 clinical medicine, male, возрастной андрогенный дефицит, реваскуляризация миокарда, мужской пол, общий тестостерон

Orthostatic Hypotension: Definition, Pathophysiology, Classification, Prognostic Aspects, Diagnostics and Treatment ; Ортостатическая гипотензия: определение, патофизиология, классификация, прогностические аспекты, диагностика и лечение

Συγγραφείς: O. Ostroumova D., M. Cherniaeva S., M. Petrova M., O. Golovina V., О. Остроумова Д., М. Черняева С., М. Петрова М., О. Головина В.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 14, No 5 (2018); 747-756 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 5 (2018); 747-756 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-5

Θεματικοί όροι: orthostatic hypotension, blood pressure, elderly, cardiovascular events, cognitive functions, ортостатическая гипотензия, артериальное давление, пожилой возраст, сердечно-сосудистые события, когнитивные функции

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1765/1725; Freeman R., Wieling W., Axelrod F.B. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. doi:10.1007/s10286-011-0119-5.; Bradbury S., Eggleston C. Postural hypotension: report of three cases. Am Heart J (St. Louis). 1925;1:73-86.; Brignole M., Moya A., de Lange F.J. et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-948. doi:10.1093/eurheartj/ehy037.; Grubb B.P. Pathophysiology and differential diagnosis of neurocardiogenic syncope. Am J Cardiol. 1999;84(8А):3Q-9Q.; Головина Г.А., Дупляков Д.В. Ортостатическая гипотензия. Взгляд кардиолога. Артериальная Гипертония. 2014;20(2):75-85.; Ricci F., De Caterina R., Fedorowski A. Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. J Am Coll Cardiol. 2015;66(7):848-60. doi:10.1016/j.jacc.2015.06.1084.; Shannon J.R., Diedrich A., Biaggioni I. et al. Water drinking as a treatment for orthostatic syndromes. Am J Med. 2002;112(5):355-60.; Sutton R. Clinical classification of syncope. Prog Cardiovasc Dis. 2013;55(4):339-44. doi:10.1016/j.pcad.2012.11.005.; Thompson W.O., Thompson P.K., Dailey M.E. The effect of posture upon the composition and volume of the blood in man. Proc Natl Acad Sci U S A. 1928;14(1):94-8.; Grubb B.P., Karas B. Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: an overview of classification, clinical evaluation, and management. Pacing Clin Electrophysiol. 1999;22(5):798-810.; Hainsworth R. Vascular capacitance: its control and importance. Rev Physiol Biochem Pharmacol. 1986;105:101-73.; Robertson D. Mechanisms of orthostatic hypotension. Curr Cardiol. 1993;8:737-45.; Атаханов Ш.Э., Робертсон Д. Ортостатическая гипотония и вегетативная недостаточность (механизмы и классификации). Кардиология. 1995;3:41-9.; Mader S.L. Postprandial hypotension in the elderly. J Am Geriatr Soc. 1988;36(1):84.; Robertson D., Wade D., Robertson R.M. Postprandial alterations in cardiovascular hemodynamics in autonomic dysfunctional states. Am J Cardiol. 1981;48(6):1048-52.; Krediet C.T., Go-Schon I.K., Kim Y.S. et al. Management of initial orthostatic hypotension: Lower body muscle tensing attenuates the transient arterial blood pressure decrease upon standing from squatting. Clin Sci (London). 2007;113(10):401-7. doi:10.1042/CS20070064.; Jordan J., Shannon J.R., Black B.K. et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation. 2000;101(5):504-9.; Masuo K., Mikami H., Ogihara T., Tuck M.L. Changes in frequency of orthostatic hypotension in elderly hypertensive patients under medications. Am J Hypertens. 1996;9(3):263-8.; Lagi A., Rossi A., Cornelli A. et al. Postural hypotension in hypertensive patients. Blood Press. 2003;12(5-6):340-4.; Mader S.L. Orthostatic hypotension. Med Clin North Am. 1989;73(6):1337-49.; Gupta V., Lipsitz L.A. Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med. 2007;120(10):841-7. doi:10.1016/j.amjmed.2007.02.023.; Goldstein D.S., Robertson D., Esler M. et al. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med. 2002;137(9):753-63.; Kanjwal K., George A., Figueredo V.M. et al. Orthostatic hypotension: definition, diagnosis and management. J Cardiovasc Med (Hagerstown) 2015;16(2):75-81. doi:10.2459/01.JCM.0000446386.01100.3.; Fedorowski A., Melander O. Syndromes of orthostatic intolerance: a hidden danger. J Intern Med. 2013;273(4):322-35. doi:10.1111/joim.12021.; Robertson D. The pathophysiology and diagnosis of orthostatic hypotension. Clin Auton Res. 2008;18 Suppl 1:2-7. doi:10.1007/s10286-007-1004-0.; Goldstein D.S., Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139-46. doi:10.1161/CIRCULATIONAHA.108.805887.; Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. J Neurol Sci. 1996;144(1-2):218-9.; Lipsitz L.A. Aging and the autonomous nervous system. In: Robertson D., Low P.A., Polinski R.J., eds. Primer on the Autonomic Nervous System. San Diego: Academic Press; 1996. pp. 79-83.; Rutan G.H., Hermanson B., Bild D.E. et al. Orthostatic hypotension in older adults: the cardiovascular health study. Hypertension. 1992;19(6 Pt 1):508-19.; Strogatz D.S., Keenan N.L., Barnett E.M., Wagner E.H. Correlates of postural hypotension in a community sample of elderly blacks and whites. J Am Geriatr Soc. 1991;39(6):562-6.; Shin C., Abbott R.D., Lee H. et al. Prevalence and correlates of orthostatic hypotension in middleaged men and women in Korea: the Korean Health and Genome Study. J Hum Hypertens. 2004;18(10):717-23. doi:10.1038/sj.jhh.1001732.; Fedorowski A., Burri P., Melander O. Orthostatic hypotension in genetically related hypertensive and normotensive individuals. J Hypertens. 2009;27(5):976-82.; Räihä I., Luutonen S., Piha J. et al. Prevalence, predisposing factors, and prognostic importance of postural hypotension. Arch Intern Med. 1995;155(9):930-5.; Lagro J., Laurenssen N.C., Schalk B.W. et al. Diastolic blood pressure drop after standing as a clinical sign for increased mortality in older falls clinic patients. J Hypertens. 2012;30(6):1195-202. doi:10.1097/HJH.0b013e328352b9fd.; Poon I.O., Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30(2):173-8. doi:10.1111/j.1365-2710.2005.00629.x.; Fedorowski A., Engstrom G., Hedblad B., Melander O. Orthostatic hypotension predicts incidence of heart failure: the Malmö Preventive Project. Am J Hypertens. 2010;23(11):1209-15. doi:10.1038/ajh.2010.150; Krolewski A.S., Warram J.H., Cupples A. et al. Hypertension, orthostatic hypotension and the microvascular complications of diabetes. J Chronic Dis. 1985;38(4):319-26.; Sasaki O., Nakahama H., Nakamura S. et al. Orthostatic hypotension at the introductory phase of haemodialysis predicts all-cause mortality. Nephrol Dial Transplant. 2005;20(2):377-81. doi:10.1093/ndt/gfh614.; Masaki K.H., Schatz I.J., Burchfiel C.M. et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation. 1998;98(21):2290-5.; Verwoert G.C., Mattace-Raso F.U., Hofman A. et al. Orthostatic hypotension and risk of cardiovascular disease in elderly people: the Rotterdam study. J Am Geriatr Soc. 2008;56(10):1816-20. doi:10.1111/j.1532-5415.2008.01946.x.; Eigenbrodt M.L., Rose K.M., Couper D.J. et al. Orthostatic hypotension as a risk factor for stroke: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1996. Stroke. 2000;31(10):2307-13.; Weiss A., Beloosesky Y., Kornowski R. et al. Influence of orthostatic hypotension on mortality among patients discharged from an acute geriatric ward. J Gen Intern Med. 2006;21(6):602-6. doi:10.1111/j.1525-1497.2006.00450.x.; Hossain M., Ooi W.L., Lipsitz L.A. Intra-individual postural blood pressure variability and stroke in elderly nursing home residents. J Clin Epidemiol. 2001;54(5):488-94.; Ricci F., Fedorowski A. Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. Eur Heart J. 2015;36:1609-17. doi:10.1093/eurheartj/ehv093.; Fedorowski A., Hedblad B., Melander O. Early postural blood pressure response and cause-specific mortality among middle-aged adults. Eur J Epidemiol. 2011;26(7):537-46. doi:10.1007/s10654-011-9578-1.; Fedorowski A., Wahlstrand B., Hedner T., Melander O. Systolic and diastolic component of orthostatic hypotension and cardiovascular events in hypertensive patients: the Captopril Prevention Project. J Hypertens. 2014;32(1):75-81. doi:10.1097/HJH.0b013e328365cd59.; Rosamond W.D., Folsom A.R., Chambless L.E. et al. Stroke incidence and survival among middleaged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30(4):736-43.; Rose K.M., Eigenbrodt M.L., Biga R.L. et al. Orthostatic hypotension predicts mortality in middleaged adults: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2006;114(7):630-6. doi: 10,1161/CIRCULATIONAHA.105.598722.; Manolio T.A., Kronmal R.A., Burke G.L. et al. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 1996;27(9):1479-86.; Fedorowski A., Hedblad B., Engström G. et al. Orthostatic hypotension and long-term incidence of atrial fibrillation: the Malmö Preventive Project. J Intern Med. 2010;268(4):383-9. doi:10.1111/j.1365-2796.2010.02261.x.; Fedorowski A., Burri P., Struck J. et al. Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort. J Intern Med. 2013;273(4):359-67. doi:10.1111/joim.12043.; Franceschini N., Rose K.M., Astor B.C. et al. Orthostatic hypotension is associated with incident chronic kidney disease: The Atherosclerosis Risk In Communities Study. Hypertension. 2010;56(6):1054-9. doi:10.1161/HYPERTENSIONAHA.110.156380.; Fleg J.L., Evans G.W., Margolis K.L. et al. Orthostatic Hypotension in the ACCORD Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension. 2016;68(4):888-95. doi:10.1161/HYPERTENSIONAHA.116.07474.; van Hateren K.J., Kleefstra N., Blanker M.H. et al. Orthostatic hypotension, diabetes, and falling in older patients: a cross-sectional study. Br J Gen Pract. 2012;62(603):e696-702. doi:10.3399/bjgp12X656838.; Matsubayashi K., Okumiya K., Wada T. et al. Postural dysregulation in systolic blood pressure is associated with worsened scoring on neurobehavioral function tests and leukoaraiosis in the older elderly living in a community. Stroke. 1997;28(11):2169-73.; Shi J., Yang S.H., Stubley L. et al. Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res. 2000;853(1):1-4.; Punchick B., Freud T., Press Y. The association between orthostatic hypotension and cognitive state among adults 65 years and older who underwent a comprehensive geriatric assessment. Medicine. 2016;95(29):e4264. doi:10.1097/MD.0000000000004264.; Gangavati A., Hajjar I., Quach L. et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011;59(3):383-9. doi:10.1111/j.1532-5415.2011.03317.x.; Cooke J., Carew S., Quinn C. et al. The prevalence and pathological correlates of orthostatic hypotension and its subtypes when measured using beat-to-beat technology in a sample of older adults living in the community. Age Ageing. 2013;42(6):709-14. doi:10.1093/ageing/aft112.; Hiitola P., Enlund H., Kettunen R. et al. Postural changes in blood pressure and the prevalence of orthostatic hypotension among homedwelling elderly aged 75 years or older. J Human Hypertens. 2009;23(1):33-9. doi:10.1038/jhh.2008.81.; Rose K.M., Couper D., Eigenbrodt M.L. et al. Orthostatic hypotension and cognitive function: the Atherosclerosis Risk in Communities Study. Neuroepidemiology. 2010;34(1):1-7. doi:10.1159/000255459.; Viramo P., Luukinen H., Koski K. et al. Orthostatic hypotension and cognitive decline in older people. J Am Geriatr Soc. 1999;47(5):600-4.; Yap P.L., Niti M., Yap K.B. et al. Orthostatic hypotension, hypotension and cognitive status: early comorbid markers of primary dementia? Dement Geriatr Cogn Disord. 2008;26(3):239-46. doi:10.1159/000160955.; Aung A.K., Corcoran S.J., Nagalingam V. et al. Prevalence, associations, and risk factors for orthostatic hypotension in medical, surgical, and trauma inpatients: an observational cohort study. Ochsner J. 2012;12(1):35-41.; Boddaert J., Tamim H., Verny M., Belmin J. Arterial stiffness is associated with orthostatic hypotension in elderly subjects with history of falls. J Am Geriatr Soc. 2004;52(4):568-72. doi:10.1111/j.1532-5415.2004.52163.x.; Shen S., He T., Chu J. et al. Uncontrolled hypertension and orthostatic hypotension in relation to standing balance in elderly hypertensive patients. Clin Interv Aging. 2015;10:897-906. doi:10.2147/CIA.S81283.; Gaxatte C., Faraj E., Lathuillerie O. et al. Alcohol and psychotropic drugs: risk factors for orthostatic hypotension in elderly fallers. J Hum Hypertens. 2017;31(4):299-304. doi:10.1038/jhh.2013.82.; Schoon Y., Lagro J., Verhoeven Y. et al. Hypotensive syndromes are not associated with cognitive impairment in geriatric patients. Am J Alzheimer’s Dis Other Demen. 2013;28(1):47-53. doi:10.1177/1533317512466692.; Allan L.M., Ballard C.G., Allen J. et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry. 2007;78(7):671-7. doi:10.1136/jnnp.2006.102343.; Elmstahl S., Widerstrom E. Orthostatic intolerance predicts mild cognitive impairment: incidence of mild cognitive impairment and dementia from the Swedish general population cohort Good Aging in Skane. Clin Interv Aging. 2014;9:1993-2002. doi:10.2147/CIA.S72316.; Peralta C., Stampfer-Kountchev M., Karner E. et al. Orthostatic hypotension and attention in Parkinson’s disease with and without dementia. J Neural Transm (Vienna). 2007;114(5):585-8. doi:10.1007/s00702-006-0615-2.; Sonnesyn H., Nilsen D.W., Rongve A. et al. High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord. 2009;28(4):307-13. doi:10.1159/000247586.; Mehrabian S., Duron E., Labouree F. et al. Relationship between orthostatic hypotension and cognitive impairment in the elderly. J Neurol Sci. 2010;299(1-2):45-8. doi:10.1016/j.jns.2010.08.056.; Bengtsson-Lindberg M., Larsson V., Minthon L. et al. Lack of orthostatic symptoms in dementia patients with orthostatic hypotension. Clin Auton Res. 2015;25(2):87-94. doi:10.1007/s10286-014-0244-z.; Frewen J., Finucane C., Savva G.M. et al. Orthostatic hypotension is associated with lower cognitive performance in adults aged 50 plus with supine hypertension. J Gerontol A Biol Sci Med Sci. 2014;69(7):878-85. doi:10.1093/gerona/glt171.; Wolters F.J., Mattace-Raso F.U., Koudstaal P.J. et al. Orthostatic Hypotension and the Long-Term Risk of Dementia: A Population-Based Study. PLOS Med. 2016;13(10):e1002143. doi:10.1371/journal.pmed.1002143.; Gibbons C.H., Schmidt P., Biaggioni I. et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567-82. doi:10.1007/s00415-016-8375-x.; Low P.A. Neurogenic orthostatic hypotension: pathophysiology and diagnosis. Am J Manag Care. 2015;21(13 Suppl):s248-57.; Biaggioni I. Treatment: special conditions: orthostatic hypotension. J Am Soc Hypertens. 2015;9(1):67-9. doi:10.1016/j.jash.2014.12.005.; White N.J. Heart-rate changes on standing in elderly patients with orthostatic hypotension. Clin Sci (London). 1980;58(5):411-3.; Рязанцева Е.Е., Мелехов А.В., Гендлин Г.Е. Артериальная гипертония и ортостатическая гипотензия: клиническая дилемма. Атмосфера. Антигипертензивная Tерапия. 2014;2:20-7.; https://www.rpcardio.com/jour/article/view/1765

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/1765
https://doi.org/10.20996/1819-6446-2018-14-5-747-756

THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE

Συγγραφείς: V. V. Yakusevich, A. Yu. Malygin, S. V. Lychenko, A. S. Petrochenko, A. V. Kabanov

Πηγή: Рациональная фармакотерапия в кардиологии, Vol 8, Iss 1, Pp 4-16 (2015)

Θεματικοί όροι: ишемический инсульт, симвастатин, высокая доза, эндотелиальная дисфункция, сердечно-сосудистые события, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

Περιγραφή αρχείου: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/393; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Σύνδεσμος πρόσβασης: https://doaj.org/article/adaa16e690724c5abbf30aeac20e478c

Perioperative assessment of troponin level in the non-cardiac interventions: is there such a need?

Συγγραφείς: A. N. Sumin

Πηγή: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 5, Pp 529-534 (2015)

Θεματικοί όροι: некардиальные операции, сердечно-сосудистые события, тропонин, скрининг, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

Περιγραφή αρχείου: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/328; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Σύνδεσμος πρόσβασης: https://doaj.org/article/b700cb195d5342caa98d59e77e3ddf96

THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE

Συγγραφείς: V. V. Yakusevich, S. V. Lychenko, A. Yu. Malygin, A. V. Kabanov, A. S. Petrochenko

Πηγή: Рациональная фармакотерапия в кардиологии, Vol 8, Iss 1, Pp 4-16 (2015)

Θεματικοί όροι: ишемический инсульт, сердечно-сосудистые события, RM1-950, симвастатин, эндотелиальная дисфункция, endothelial dysfunction, 3. Good health, cardiovascular events, 03 medical and health sciences, 0302 clinical medicine, high dose, высокая доза, RC666-701, ischemic stroke, simvastatin, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology

Σύνδεσμος πρόσβασης: https://www.rpcardio.com/jour/article/download/393/412
https://doaj.org/article/adaa16e690724c5abbf30aeac20e478c
https://doaj.org/article/f45525b2371346238fdbe1b0c223d45b
https://www.rpcardio.com/jour/article/download/393/412
https://www.rpcardio.com/jour/article/view/393